{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,19]],"date-time":"2025-11-19T17:13:26Z","timestamp":1763572406736,"version":"3.41.0"},"reference-count":155,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2017,12,1]],"date-time":"2017-12-01T00:00:00Z","timestamp":1512086400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Medicinal Chemistry"],"published-print":{"date-parts":[[2017,12]]},"DOI":"10.1016\/j.ejmech.2017.07.031","type":"journal-article","created":{"date-parts":[[2017,7,20]],"date-time":"2017-07-20T09:46:55Z","timestamp":1500544015000},"page":"163-178","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":55,"special_numbering":"C","title":["Heme oxygenase-1: A new druggable target in the management of chronic and acute myeloid leukemia"],"prefix":"10.1016","volume":"142","author":[{"given":"Loredana","family":"Salerno","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giuseppe","family":"Romeo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria N.","family":"Modica","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emanuele","family":"Amata","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Valeria","family":"Sorrenti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ignazio","family":"Barbagallo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1856-0308","authenticated-orcid":false,"given":"Valeria","family":"Pittal\u00e0","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejmech.2017.07.031_bib1","doi-asserted-by":"crossref","first-page":"2375","DOI":"10.1182\/blood-2016-01-643569","article-title":"The 2016 revision of the World Health Organization classification of lymphoid neoplasms","volume":"127","author":"Swerdlow","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.ejmech.2017.07.031_bib2","doi-asserted-by":"crossref","first-page":"2361","DOI":"10.1182\/blood-2016-03-657379","article-title":"Introduction to a review series: the 2016 revision of the WHO classification of tumors of hematopoietic and lymphoid tissues","volume":"127","author":"Cazzola","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.ejmech.2017.07.031_bib3","first-page":"83","article-title":"WHO classification of tumours of haematopoietic and lymphoid tissues in 2008: an overview","volume":"102","author":"Sabattini","year":"2010","journal-title":"Pathologica"},{"key":"10.1016\/j.ejmech.2017.07.031_bib4","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.1182\/blood-2016-03-643544","article-title":"The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia","volume":"127","author":"Arber","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.ejmech.2017.07.031_bib5","doi-asserted-by":"crossref","first-page":"541","DOI":"10.3324\/haematol.2015.139337","article-title":"Chronic myeloid leukemia: reminiscences and dreams","volume":"101","author":"Mughal","year":"2016","journal-title":"Haematologica"},{"key":"10.1016\/j.ejmech.2017.07.031_bib6","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.leukres.2014.10.005","article-title":"Comparative efficacy of tyrosine kinase inhibitor treatments in the third-line setting, for chronic-phase chronic myelogenous leukemia after failure of second-generation tyrosine kinase inhibitors","volume":"39","author":"Lipton","year":"2015","journal-title":"Leuk. Res."},{"key":"10.1016\/j.ejmech.2017.07.031_bib7","doi-asserted-by":"crossref","first-page":"3221","DOI":"10.1007\/s00018-016-2223-0","article-title":"Role of Nrf2\/HO-1 system in development, oxidative stress response and diseases: an evolutionarily conserved mechanism","volume":"73","author":"Loboda","year":"2016","journal-title":"Cell Mol. Life Sci."},{"key":"10.1016\/j.ejmech.2017.07.031_bib8","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1124\/pr.107.07104","article-title":"Pharmacological and clinical aspects of heme oxygenase","volume":"60","author":"Abraham","year":"2008","journal-title":"Pharmacol. Rev."},{"key":"10.1016\/j.ejmech.2017.07.031_bib9","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1146\/annurev.pharmtox.010909.105600","article-title":"Mechanisms of cell protection by heme oxygenase-1","volume":"50","author":"Gozzelino","year":"2010","journal-title":"Annu. Rev. Pharmacol. Toxicol."},{"key":"10.1016\/j.ejmech.2017.07.031_bib10","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.trsl.2015.06.011","article-title":"Targeting heme oxygenase-1 and carbon monoxide for therapeutic modulation of inflammation","volume":"167","author":"Ryter","year":"2016","journal-title":"Transl. Res."},{"key":"10.1016\/j.ejmech.2017.07.031_bib11","doi-asserted-by":"crossref","first-page":"1810","DOI":"10.1089\/ars.2013.5658","article-title":"Heme oxygenase-1 as a target for drug discovery","volume":"20","author":"Motterlini","year":"2014","journal-title":"Antioxid. Redox Signal"},{"key":"10.1016\/j.ejmech.2017.07.031_bib12","article-title":"Therapeutic potential of caffeic acid Phenethyl ester (CAPE) in diabetes","author":"Pittal\u00e0","year":"2016","journal-title":"Curr. Med. Chem."},{"key":"10.1016\/j.ejmech.2017.07.031_bib13","doi-asserted-by":"crossref","DOI":"10.2174\/1381612823666170210151411","article-title":"Novel caffeic acid Phenethyl ester (cape) analogues as inducers of heme Oxygenase-1","author":"Pittala","year":"2017","journal-title":"Curr. Pharm. Des."},{"key":"10.1016\/j.ejmech.2017.07.031_bib14","doi-asserted-by":"crossref","first-page":"1701","DOI":"10.1042\/CS20170157","article-title":"Role of the Nrf2\/HO-1 axis in bronchopulmonary dysplasia and hyperoxic lung injuries","volume":"131","author":"Amata","year":"2017","journal-title":"Clin. Sci. (Lond)"},{"key":"10.1016\/j.ejmech.2017.07.031_bib15","doi-asserted-by":"crossref","DOI":"10.2174\/0929867324666170616110748","article-title":"Effects of polyphenolic derivatives on heme oxygenase-system in metabolic dysfunctions","author":"Pittala","year":"2017","journal-title":"Curr. Med. Chem."},{"key":"10.1016\/j.ejmech.2017.07.031_bib16","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1097\/01.mop.0000156270.25640.5a","article-title":"Metalloporphyrins for the treatment of neonatal jaundice","volume":"17","author":"Dennery","year":"2005","journal-title":"Curr. Opin. Pediatr."},{"key":"10.1016\/j.ejmech.2017.07.031_bib17","doi-asserted-by":"crossref","first-page":"1958174","DOI":"10.1155\/2016\/1958174","article-title":"The nrf2\/HO-1 Axis in cancer cell growth and chemoresistance","volume":"1","author":"Furfaro","year":"2016","journal-title":"Oxid. Med. Cell Longev."},{"key":"10.1016\/j.ejmech.2017.07.031_bib18","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/j.ejmech.2015.04.003","article-title":"Novel imidazole derivatives as heme oxygenase-1 (HO-1) and heme oxygenase-2 (HO-2) inhibitors and their cytotoxic activity in human-derived cancer cell lines","volume":"96","author":"Salerno","year":"2015","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2017.07.031_bib19","doi-asserted-by":"crossref","first-page":"3711","DOI":"10.2174\/0929867311320300003","article-title":"A\u00a0focus on heme oxygenase-1 (HO-1) inhibitors","volume":"20","author":"Pittala","year":"2013","journal-title":"Curr. Med. Chem."},{"key":"10.1016\/j.ejmech.2017.07.031_bib20","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1016\/j.freeradbiomed.2013.10.819","article-title":"Oncogenic potential of Nrf2 and its principal target protein heme oxygenase-1","volume":"67","author":"Na","year":"2014","journal-title":"Free Radic. Biol. Med."},{"key":"10.1016\/j.ejmech.2017.07.031_bib21","doi-asserted-by":"crossref","first-page":"337","DOI":"10.2174\/1568009614666140320111306","article-title":"The expression, function and targeting of haem oxygenase-1 in cancer","volume":"14","author":"Hjortso","year":"2014","journal-title":"Curr. Cancer Drug Targets"},{"key":"10.1016\/j.ejmech.2017.07.031_bib22","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1186\/s12929-015-0128-0","article-title":"Heme oxygenase-1: emerging target of cancer therapy","volume":"22","author":"Chau","year":"2015","journal-title":"J.\u00a0Biomed. Sci."},{"key":"10.1016\/j.ejmech.2017.07.031_bib23","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.vph.2015.09.004","article-title":"HO-1\/CO system in tumor growth, angiogenesis and metabolism - targeting HO-1 as an anti-tumor therapy","volume":"74","author":"Loboda","year":"2015","journal-title":"Vasc. Pharmacol."},{"key":"10.1016\/j.ejmech.2017.07.031_bib24","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.3390\/cancers3021605","article-title":"The role of nrf2 and cytoprotection in regulating chemotherapy resistance of human leukemia cells","volume":"3","author":"Rushworth","year":"2011","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.ejmech.2017.07.031_bib25","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1089\/ars.2011.4258","article-title":"Redox control of leukemia: from molecular mechanisms to therapeutic opportunities","volume":"18","author":"Irwin","year":"2013","journal-title":"Antioxid. Redox Signal"},{"key":"10.1016\/j.ejmech.2017.07.031_bib26","doi-asserted-by":"crossref","first-page":"3790","DOI":"10.1158\/1078-0432.CCR-04-2159","article-title":"Inhibition of heme oxygenase-1 increases responsiveness of pancreatic cancer cells to anticancer treatment","volume":"11","author":"Berberat","year":"2005","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ejmech.2017.07.031_bib27","doi-asserted-by":"crossref","first-page":"2765","DOI":"10.2174\/1381612811319150012","article-title":"Nuclear translocation of heme oxygenase-1 confers resistance to imatinib in chronic myeloid leukemia cells","volume":"19","author":"Tibullo","year":"2013","journal-title":"Curr. Pharm. Des."},{"key":"10.1016\/j.ejmech.2017.07.031_bib28","doi-asserted-by":"crossref","first-page":"5145","DOI":"10.1016\/j.bmc.2013.06.040","article-title":"Evaluation of novel aryloxyalkyl derivatives of imidazole and 1,2,4-triazole as heme oxygenase-1 (HO-1) inhibitors and their antitumor properties","volume":"21","author":"Salerno","year":"2013","journal-title":"Bioorg Med. Chem."},{"key":"10.1016\/j.ejmech.2017.07.031_bib29","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.leukres.2017.01.005","article-title":"Current approach to the treatment of chronic myeloid leukaemia","volume":"55","author":"Pasic","year":"2017","journal-title":"Leuk. Res."},{"key":"10.1016\/j.ejmech.2017.07.031_bib30","doi-asserted-by":"crossref","first-page":"1392","DOI":"10.1016\/S0140-6736(95)92596-1","volume":"345","author":"Allan","year":"1995","journal-title":"Lancet"},{"key":"10.1016\/j.ejmech.2017.07.031_bib31","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1056\/NEJMoa022457","article-title":"Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia","volume":"348","author":"O'Brien","year":"2003","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.ejmech.2017.07.031_bib32","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1007\/s12254-016-0299-8","article-title":"Short overview on the current treatment of chronic myeloid leukemia in chronic phase","volume":"9","author":"Schmidt","year":"2016","journal-title":"Memo"},{"key":"10.1016\/j.ejmech.2017.07.031_bib33","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1002\/ajh.24249","article-title":"Chronic myeloid leukemia: first-line drug of choice","volume":"91","author":"Jabbour","year":"2016","journal-title":"Am. J. Hematol."},{"key":"10.1016\/j.ejmech.2017.07.031_bib34","doi-asserted-by":"crossref","first-page":"e2014003","DOI":"10.4084\/mjhid.2014.003","article-title":"Second-generation tyrosine kinase inhibitors (Tki) as salvage therapy for resistant or intolerant patients to prior TKIs","volume":"6","author":"Breccia","year":"2014","journal-title":"Mediterr. J. Hematol. Infect. Dis."},{"key":"10.1016\/j.ejmech.2017.07.031_bib35","doi-asserted-by":"crossref","first-page":"3540","DOI":"10.1182\/blood-2007-03-080689","article-title":"Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is effective in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase following imatinib resistance and intolerance","volume":"110","author":"Kantarjian","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.ejmech.2017.07.031_bib36","doi-asserted-by":"crossref","first-page":"1783","DOI":"10.1056\/NEJMoa1306494","article-title":"For the PACE investigators, a phase 2 trial of ponatinib in Philadelphia chromosome-positive leukemias","volume":"369","author":"Cortes","year":"2013","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.ejmech.2017.07.031_bib37","doi-asserted-by":"crossref","first-page":"1767","DOI":"10.1038\/sj.leu.2404318","article-title":"Frequency and clinical significance of BCR-ABL mutations in patients with chronic myeloid leukemia treated with imatinib mesylate","volume":"20","author":"Jabbour","year":"2006","journal-title":"Leukemia"},{"key":"10.1016\/j.ejmech.2017.07.031_bib38","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1182\/blood.V126.23.138.138","article-title":"ABL001, a potent, allosteric inhibitor of BCR-ABL, exhibits safety and promising single- agent activity in a phase I study of patients with CML with failure of prior TKI therapy","volume":"126","author":"Ottmann","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.ejmech.2017.07.031_bib39","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1016\/j.clml.2013.03.020","article-title":"Subcutaneous omacetaxine mepesuccinate in patients with chronic-phase chronic myeloid leukemia previously treated with 2 or more tyrosine kinase inhibitors including imatinib","volume":"13","author":"Cortes","year":"2013","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"10.1016\/j.ejmech.2017.07.031_bib40","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1182\/blood-2009-07-235358","article-title":"Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet","volume":"115","author":"Dohner","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.ejmech.2017.07.031_bib41","doi-asserted-by":"crossref","first-page":"976","DOI":"10.3324\/haematol.13345","article-title":"Molecular characterization of acute myeloid leukemia","volume":"93","author":"Dohner","year":"2008","journal-title":"Haematologica"},{"key":"10.1016\/j.ejmech.2017.07.031_bib42","doi-asserted-by":"crossref","first-page":"2209","DOI":"10.1056\/NEJMoa1516192","article-title":"Genomic classification and prognosis in acute myeloid leukemia","volume":"374","author":"Papaemmanuil","year":"2016","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.ejmech.2017.07.031_bib43","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1200\/JCO.2010.30.2554","article-title":"Molecular genetics of adult acute myeloid leukemia: prognostic and therapeutic implications","volume":"29","author":"Marcucci","year":"2011","journal-title":"J.\u00a0Clin. Oncol."},{"key":"10.1016\/j.ejmech.2017.07.031_bib44","doi-asserted-by":"crossref","first-page":"1894","DOI":"10.1016\/S0140-6736(06)69780-8","article-title":"Acute myeloid leukaemia","volume":"368","author":"Estey","year":"2006","journal-title":"Lancet"},{"key":"10.1016\/j.ejmech.2017.07.031_bib45","doi-asserted-by":"crossref","first-page":"3181","DOI":"10.1002\/cncr.23927","article-title":"Treatment of core-binding-factor in acute myelogenous leukemia with fludarabine, cytarabine, and granulocyte colony-stimulating factor results in improved event-free survival","volume":"113","author":"Borthakur","year":"2008","journal-title":"Cancer"},{"key":"10.1016\/j.ejmech.2017.07.031_bib46","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.critrevonc.2016.12.004","article-title":"Frontline treatment of acute myeloid leukemia in adults","volume":"110","author":"Tamamyan","year":"2017","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"10.1016\/j.ejmech.2017.07.031_bib47","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.clml.2014.08.006","article-title":"Progress in acute myeloid leukemia","volume":"15","author":"Kadia","year":"2015","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"10.1016\/j.ejmech.2017.07.031_bib48","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1056\/NEJMoa1300874","article-title":"Retinoic acid and arsenic trioxide for acute promyelocytic leukemia","volume":"369","author":"Lo-Coco","year":"2013","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.ejmech.2017.07.031_bib49","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/j.blre.2016.02.001","article-title":"Update on rational targeted therapy in AML","volume":"30","author":"Shafer","year":"2016","journal-title":"Blood Rev."},{"key":"10.1016\/j.ejmech.2017.07.031_bib50","first-page":"39","article-title":"Novel therapeutic options in acute myeloid leukemia","volume":"6","author":"Medinger","year":"2016","journal-title":"Leuk. Res. Rep."},{"key":"10.1016\/j.ejmech.2017.07.031_bib51","doi-asserted-by":"crossref","first-page":"2363","DOI":"10.1158\/1078-0432.CCR-13-2052","article-title":"Reversal of acquired drug resistance in FLT3-mutated acute myeloid leukemia cells via distinct drug combination strategies","volume":"20","author":"Zhang","year":"2014","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ejmech.2017.07.031_bib52","unstructured":"Ponatinib, Ponatinib for FLT3-ITD Acute Myelogenous Leukemia (PONATINIB-AML). ClinicalTrials.gov Identifier: NCT02428543."},{"key":"10.1016\/j.ejmech.2017.07.031_bib53","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1002\/cncr.22496","article-title":"A\u00a0comparison of low-dose cytarabine and hydroxyurea with or without all-trans retinoic acid for acute myeloid leukemia and high-risk myelodysplastic syndrome in patients not considered fit for intensive treatment","volume":"109","author":"Burnett","year":"2007","journal-title":"Cancer"},{"key":"10.1016\/j.ejmech.2017.07.031_bib54","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1200\/JCO.1990.8.2.272","article-title":"Low-dose cytarabine versus intensive chemotherapy in the treatment of acute nonlymphocytic leukemia in the elderly","volume":"8","author":"Tilly","year":"1990","journal-title":"J.\u00a0Clin. Oncol."},{"key":"10.1016\/j.ejmech.2017.07.031_bib55","doi-asserted-by":"crossref","first-page":"4179","DOI":"10.1182\/blood-2008-07-172007","article-title":"Age and acute myeloid leukemia: real world data on decision to treat and outcomes from the Swedish Acute Leukemia Registry","volume":"113","author":"Juliusson","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.ejmech.2017.07.031_bib56","doi-asserted-by":"crossref","first-page":"669","DOI":"10.5858\/2006-130-669-IROAO","article-title":"Imatinib resistance: obstacles and opportunities","volume":"130","author":"Litzow","year":"2006","journal-title":"Arch. Pathol. Lab. Med."},{"key":"10.1016\/j.ejmech.2017.07.031_bib57","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1182\/asheducation-2007.1.371","article-title":"Medical management of CML","author":"Shah","year":"2007","journal-title":"Hematol. Am. Soc. Hematol. Educ. Program"},{"key":"10.1016\/j.ejmech.2017.07.031_bib58","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/S1535-6108(02)00096-X","article-title":"Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia","volume":"2","author":"Shah","year":"2002","journal-title":"Cancer Cell"},{"key":"10.1016\/j.ejmech.2017.07.031_bib59","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1126\/science.1062538","article-title":"Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification","volume":"293","author":"Gorre","year":"2001","journal-title":"Science"},{"key":"10.1016\/j.ejmech.2017.07.031_bib60","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.blre.2005.01.008","article-title":"Molecular monitoring of BCR-ABL as a guide to clinical management in chronic myeloid leukaemia","volume":"20","author":"Hughes","year":"2006","journal-title":"Blood Rev."},{"key":"10.1016\/j.ejmech.2017.07.031_bib61","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1056\/NEJMp038130","article-title":"Minimal residual disease in chronic myeloid leukemia","volume":"349","author":"Lowenberg","year":"2003","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.ejmech.2017.07.031_bib62","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1016\/S0092-8674(03)00190-9","article-title":"Mechanisms of autoinhibition and STI-571\/imatinib resistance revealed by mutagenesis of BCR-ABL","volume":"112","author":"Azam","year":"2003","journal-title":"Cell"},{"key":"10.1016\/j.ejmech.2017.07.031_bib63","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1182\/blood-2002-09-2896","article-title":"Detection of BCR-ABL mutations in patients with CML treated with imatinib is virtually always accompanied by clinical resistance, and mutations in the ATP phosphate-binding loop (P-loop) are associated with a poor prognosis","volume":"102","author":"Branford","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.ejmech.2017.07.031_bib64","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1038\/nrd2324","article-title":"Flying under the radar: the new wave of BCR-ABL inhibitors","volume":"6","author":"Quintas-Cardama","year":"2007","journal-title":"Nat. Rev. Drug Discov."},{"issue":"Suppl 1","key":"10.1016\/j.ejmech.2017.07.031_bib65","doi-asserted-by":"crossref","first-page":"12","DOI":"10.3109\/10428194.2010.546920","article-title":"Mechanisms of resistance to BCR-ABL kinase inhibitors","volume":"52","author":"Diamond","year":"2011","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.ejmech.2017.07.031_bib66","doi-asserted-by":"crossref","first-page":"2190","DOI":"10.1038\/sj.leu.2402741","article-title":"Molecular and chromosomal mechanisms of resistance to imatinib (STI571) therapy","volume":"16","author":"Hochhaus","year":"2002","journal-title":"Leukemia"},{"key":"10.1016\/j.ejmech.2017.07.031_bib67","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1038\/sj.leu.2403426","article-title":"Imatinib therapy in chronic myelogenous leukemia: strategies to avoid and overcome resistance","volume":"18","author":"Hochhaus","year":"2004","journal-title":"Leukemia"},{"key":"10.1016\/j.ejmech.2017.07.031_bib68","doi-asserted-by":"crossref","first-page":"2075","DOI":"10.1056\/NEJMoa1205127","article-title":"Ponatinib in refractory Philadelphia chromosome-positive leukemias","volume":"367","author":"Cortes","year":"2012","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.ejmech.2017.07.031_bib69","doi-asserted-by":"crossref","first-page":"7374","DOI":"10.1158\/1078-0432.CCR-06-1516","article-title":"G.W.P.o.C.M. Leukemia, Contribution of ABL kinase domain mutations to imatinib resistance in different subsets of Philadelphia-positive patients: by the GIMEMA Working Party on Chronic Myeloid Leukemia","volume":"12","author":"Soverini","year":"2006","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ejmech.2017.07.031_bib70","doi-asserted-by":"crossref","first-page":"4100","DOI":"10.1200\/JCO.2005.05.531","volume":"23","author":"Soverini","year":"2005","journal-title":"J.\u00a0Clin. Oncol."},{"key":"10.1016\/j.ejmech.2017.07.031_bib71","doi-asserted-by":"crossref","first-page":"4143","DOI":"10.1182\/blood-2006-09-046839","article-title":"Dasatinib induces significant hematologic and cytogenetic responses in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in accelerated phase","volume":"109","author":"Guilhot","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.ejmech.2017.07.031_bib72","doi-asserted-by":"crossref","first-page":"6322","DOI":"10.1182\/blood-2008-11-186817","article-title":"Phase 3 study of dasatinib 140 mg once daily versus 70 mg twice daily in patients with chronic myeloid leukemia in accelerated phase resistant or intolerant to imatinib: 15-month median follow-up","volume":"113","author":"Kantarjian","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.ejmech.2017.07.031_bib73","doi-asserted-by":"crossref","first-page":"1758","DOI":"10.1182\/blood.V95.5.1758.005a41_1758_1766","article-title":"Induction of resistance to the Abelson inhibitor STI571 in human leukemic cells through gene amplification","volume":"95","author":"le Coutre","year":"2000","journal-title":"Blood"},{"key":"10.1016\/j.ejmech.2017.07.031_bib74","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/S1470-2045(03)00979-3","article-title":"Molecular mechanisms of resistance to imatinib in Philadelphia-chromosome-positive leukaemias","volume":"4","author":"Gambacorti-Passerini","year":"2003","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.ejmech.2017.07.031_bib75","doi-asserted-by":"crossref","first-page":"3496","DOI":"10.1182\/blood-2006-07-036012","article-title":"Trough imatinib plasma levels are associated with both cytogenetic and molecular responses to standard-dose imatinib in chronic myeloid leukemia","volume":"109","author":"Picard","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.ejmech.2017.07.031_bib76","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1007\/s00280-003-0741-6","article-title":"Pharmacokinetics and cellular uptake of imatinib and its main metabolite CGP74588","volume":"53","author":"le Coutre","year":"2004","journal-title":"Cancer Chemother. Pharmacol."},{"key":"10.1016\/j.ejmech.2017.07.031_bib77","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1200\/JCO.2004.03.050","article-title":"Pharmacokinetics and pharmacodynamics of imatinib in a phase I trial with chronic myeloid leukemia patients","volume":"22","author":"Peng","year":"2004","journal-title":"J.\u00a0Clin. Oncol."},{"key":"10.1016\/j.ejmech.2017.07.031_bib78","doi-asserted-by":"crossref","first-page":"5401","DOI":"10.1182\/blood-2008-12-196543","article-title":"Prevalence, determinants, and outcomes of nonadherence to imatinib therapy in patients with chronic myeloid leukemia: the ADAGIO study","volume":"113","author":"Noens","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.ejmech.2017.07.031_bib79","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1007\/BF02353475","article-title":"Cytochrome P4503A (CYP3A) metabolism: prediction of in\u00a0vivo activity in humans","volume":"24","author":"Wilkinson","year":"1996","journal-title":"J.\u00a0Pharmacokinet. Biopharm."},{"key":"10.1016\/j.ejmech.2017.07.031_bib80","doi-asserted-by":"crossref","first-page":"7394","DOI":"10.1158\/1078-0432.CCR-07-0346","article-title":"Influence of CYP3A4 inhibition on the steady-state pharmacokinetics of imatinib","volume":"13","author":"van Erp","year":"2007","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ejmech.2017.07.031_bib81","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1007\/s00228-009-0772-y","article-title":"CYP3A activity influences imatinib response in patients with chronic myeloid leukemia: a pilot study on in\u00a0vivo CYP3A activity","volume":"66","author":"Green","year":"2010","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"10.1016\/j.ejmech.2017.07.031_bib82","doi-asserted-by":"crossref","first-page":"879","DOI":"10.2165\/00003088-200544090-00001","article-title":"Clinical pharmacokinetics of imatinib","volume":"44","author":"Peng","year":"2005","journal-title":"Clin. Pharmacokinet."},{"key":"10.1016\/j.ejmech.2017.07.031_bib83","first-page":"625","article-title":"Alpha1 acid glycoprotein binds to imatinib (STI571) and substantially alters its pharmacokinetics in chronic myeloid leukemia patients","volume":"9","author":"Gambacorti-Passerini","year":"2003","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ejmech.2017.07.031_bib84","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1182\/blood.V99.2.713","article-title":"Alpha1-acid glycoprotein expressed in the plasma of chronic myeloid leukemia patients does not mediate significant in\u00a0vitro resistance to STI571","volume":"99","author":"Jorgensen","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.ejmech.2017.07.031_bib85","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1158\/1078-0432.CCR-10-2250","article-title":"Drug transporters and imatinib treatment: implications for clinical practice","volume":"17","author":"Eechoute","year":"2011","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ejmech.2017.07.031_bib86","doi-asserted-by":"crossref","first-page":"3739","DOI":"10.1182\/blood-2003-12-4276","article-title":"Active transport of imatinib into and out of cells: implications for drug resistance","volume":"104","author":"Thomas","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.ejmech.2017.07.031_bib87","doi-asserted-by":"crossref","first-page":"193","DOI":"10.3324\/haematol.2012.066480","article-title":"Association between imatinib transporters and metabolizing enzymes genotype and response in newly diagnosed chronic myeloid leukemia patients receiving imatinib therapy","volume":"98","author":"Angelini","year":"2013","journal-title":"Haematologica"},{"key":"10.1016\/j.ejmech.2017.07.031_bib88","doi-asserted-by":"crossref","first-page":"907","DOI":"10.3324\/haematol.2011.056457","article-title":"Chronic phase chronic myeloid leukemia patients with low OCT-1 activity randomized to high-dose imatinib achieve better responses and have lower failure rates than those randomized to standard-dose imatinib","volume":"97","author":"White","year":"2012","journal-title":"Haematologica"},{"key":"10.1016\/j.ejmech.2017.07.031_bib89","doi-asserted-by":"crossref","first-page":"3881","DOI":"10.1158\/1078-0432.CCR-07-5095","article-title":"Dasatinib cellular uptake and efflux in chronic myeloid leukemia cells: therapeutic implications","volume":"14","author":"Hiwase","year":"2008","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ejmech.2017.07.031_bib90","doi-asserted-by":"crossref","first-page":"2189","DOI":"10.1007\/s00018-004-4001-7","article-title":"Alternative splicing of Bcl-2-related genes: functional consequences and potential therapeutic applications","volume":"61","author":"Akgul","year":"2004","journal-title":"Cell Mol. Life Sci."},{"key":"10.1016\/j.ejmech.2017.07.031_bib91","doi-asserted-by":"crossref","first-page":"e0138377","DOI":"10.1371\/journal.pone.0138377","article-title":"Mitochondrial profiling of acute myeloid leukemia in the assessment of response to apoptosis modulating drugs","volume":"10","author":"Ishizawa","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.ejmech.2017.07.031_bib92","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1016\/j.cell.2012.08.038","article-title":"Relative mitochondrial priming of myeloblasts and normal HSCs determines chemotherapeutic success in AML","volume":"151","author":"Vo","year":"2012","journal-title":"Cell"},{"key":"10.1016\/j.ejmech.2017.07.031_bib93","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.2147\/OTT.S33375","article-title":"IAP proteins as targets for drug development in oncology","volume":"9","author":"Dubrez","year":"2013","journal-title":"Onco Targets Ther."},{"key":"10.1016\/j.ejmech.2017.07.031_bib94","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.canlet.2015.05.034","article-title":"AML sensitivity to YM155 is modulated through AKT and Mcl-1","volume":"366","author":"de Necochea-Campion","year":"2015","journal-title":"Cancer Lett."},{"key":"10.1016\/j.ejmech.2017.07.031_bib95","first-page":"1","article-title":"Aberrant splicing and drug resistance in AML","volume":"85","author":"de Necochea-Campion","year":"2016","journal-title":"J.\u00a0Hematol. Oncol."},{"key":"10.1016\/j.ejmech.2017.07.031_bib96","doi-asserted-by":"crossref","first-page":"5987","DOI":"10.1073\/pnas.91.13.5987","article-title":"Identification of binding sites for transcription factors NF-kappa B and AP-2 in the promoter region of the human heme oxygenase 1 gene","volume":"91","author":"Lavrovsky","year":"1994","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.ejmech.2017.07.031_bib97","doi-asserted-by":"crossref","first-page":"3465","DOI":"10.1182\/blood-2003-08-2781","article-title":"Kaposi sarcoma-associated herpesvirus (KSHV) induces heme oxygenase-1 expression and activity in KSHV-infected endothelial cells","volume":"103","author":"McAllister","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.ejmech.2017.07.031_bib98","doi-asserted-by":"crossref","first-page":"3148","DOI":"10.1158\/0008-5472.CAN-03-1200","article-title":"Identification of heme oxygenase-1 as a novel BCR\/ABL-dependent survival factor in chronic myeloid leukemia","volume":"64","author":"Mayerhofer","year":"2004","journal-title":"Cancer Res."},{"key":"10.1016\/j.ejmech.2017.07.031_bib99","doi-asserted-by":"crossref","first-page":"E99","DOI":"10.1016\/j.jss.2010.05.058","article-title":"Correlation of Nrf2, HO-1, and MRP3 in gallbladder cancer and their relationships to clinicopathologic features and survival","volume":"164","author":"Wang","year":"2010","journal-title":"J.\u00a0Surg. Res."},{"key":"10.1016\/j.ejmech.2017.07.031_bib100","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1089\/ars.2013.5184","article-title":"Interplay between heme Oxygenase-1 and miR-378 affects non-small cell lung carcinoma growth, vascularization, and metastasis","volume":"19","author":"Skrzypek","year":"2013","journal-title":"Antioxid. Redox Sign"},{"key":"10.1016\/j.ejmech.2017.07.031_bib101","doi-asserted-by":"crossref","first-page":"680","DOI":"10.4149\/neo_2014_083","article-title":"MiR-200c sensitizes clear-cell renal cell carcinoma cells to sorafenib and imatinib by targeting heme oxygenase-1","volume":"61","author":"Gao","year":"2014","journal-title":"Neoplasma"},{"key":"10.1016\/j.ejmech.2017.07.031_bib102","first-page":"1826","article-title":"Ubiquitin-proteasome system mediates heme oxygenase-1 degradation through endoplasmic reticulum-associated degradation pathway","volume":"1783","author":"Lin","year":"2008","journal-title":"Bba-Mol Cell Res."},{"key":"10.1016\/j.ejmech.2017.07.031_bib103","doi-asserted-by":"crossref","first-page":"2325","DOI":"10.1038\/onc.2012.244","article-title":"TRC8 suppresses tumorigenesis through targeting heme oxygenase-1 for ubiquitination and degradation","volume":"32","author":"Lin","year":"2013","journal-title":"Oncogene"},{"key":"10.1016\/j.ejmech.2017.07.031_bib104","doi-asserted-by":"crossref","first-page":"3148","DOI":"10.1158\/0008-5472.CAN-03-1200","article-title":"Identification of heme oxygenase-1 as a novel BCR\/ABL-dependent survival factor in chronic myeloid leukemia","volume":"64","author":"Mayerhofer","year":"2004","journal-title":"Cancer Res."},{"key":"10.1016\/j.ejmech.2017.07.031_bib105","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1182\/blood-2005-12-040972","article-title":"Bcr-Abl signaling through the PI-3\/S6 kinase pathway inhibits nuclear translocation of the transcription factor Bach2, which represses the antiapoptotic factor heme oxygenase-1","volume":"109","author":"Yoshida","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.ejmech.2017.07.031_bib106","doi-asserted-by":"crossref","DOI":"10.1089\/ars.2016.6735","article-title":"The heme oxygenase system in hematological malignancies","author":"Li Volti","year":"2017","journal-title":"Antioxid. Redox Signal"},{"key":"10.1016\/j.ejmech.2017.07.031_bib107","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.biopha.2015.12.029","article-title":"Heme oxygenase-1 contributes to imatinib resistance by promoting autophagy in chronic myeloid leukemia through disrupting the mTOR signaling pathway","volume":"78","author":"Cao","year":"2016","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.ejmech.2017.07.031_bib108","first-page":"2795","article-title":"Over-expression of heme oxygenase-1 in peripheral blood predicts the progression and relapse risk of chronic myeloid leukemia","volume":"127","author":"Wei","year":"2014","journal-title":"Chin. Med. J. Engl."},{"key":"10.1016\/j.ejmech.2017.07.031_bib109","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/j.canlet.2015.07.044","article-title":"Tumor microenvironment and cancer therapy resistance","volume":"380","author":"Sun","year":"2016","journal-title":"Cancer Lett."},{"key":"10.1016\/j.ejmech.2017.07.031_bib110","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.biopha.2017.04.076","article-title":"Overexpression of heme oxygenase-1 in bone marrow stromal cells promotes microenvironment-mediated imatinib resistance in chronic myeloid leukemia","volume":"91","author":"Liu","year":"2017","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.ejmech.2017.07.031_bib111","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1021\/bc020010k","article-title":"Pegylated zinc protoporphyrin: a water-soluble heme oxygenase inhibitor with tumor-targeting capacity","volume":"13","author":"Sahoo","year":"2002","journal-title":"Bioconjug Chem."},{"key":"10.1016\/j.ejmech.2017.07.031_bib112","doi-asserted-by":"crossref","first-page":"1871","DOI":"10.1016\/j.biomaterials.2006.11.051","article-title":"High-loading nanosized micelles of copoly(styrene-maleic acid)-zinc protoporphyrin for targeted delivery of a potent heme oxygenase inhibitor","volume":"28","author":"Iyer","year":"2007","journal-title":"Biomaterials"},{"key":"10.1016\/j.ejmech.2017.07.031_bib113","doi-asserted-by":"crossref","first-page":"2200","DOI":"10.1182\/blood-2006-11-055723","article-title":"Targeting of heat shock protein 32 (Hsp32)\/heme oxygenase-1 (HO-1) in leukemic cells in chronic myeloid leukemia: a novel approach to overcome resistance against imatinib","volume":"111","author":"Mayerhofer","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.ejmech.2017.07.031_bib114","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1111\/cbdd.12015","article-title":"Evaluation of imidazole-based compounds as heme oxygenase-1 inhibitors","volume":"80","author":"Sorrenti","year":"2012","journal-title":"Chem. Biol. Drug Des."},{"key":"10.1016\/j.ejmech.2017.07.031_bib115","doi-asserted-by":"crossref","DOI":"10.1002\/cmdc.201700321","article-title":"Heme oxygenase database (HemeOxDB) and QSAR analysis of isoform 1 inhibitors","author":"Amata","year":"2017","journal-title":"ChemMedChem"},{"key":"10.1016\/j.ejmech.2017.07.031_bib116","doi-asserted-by":"crossref","first-page":"12558","DOI":"10.1074\/jbc.M114.626960","article-title":"Induction of heme oxygenase-1 by Na+-H+ exchanger 1 protein plays a crucial role in imatinib-resistant chronic myeloid leukemia cells","volume":"290","author":"Ma","year":"2015","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.ejmech.2017.07.031_bib117","doi-asserted-by":"crossref","first-page":"519","DOI":"10.5507\/bp.2015.060","article-title":"A\u00a0minireview on NHE1 inhibitors. A rediscovered hope in oncohematology","volume":"159","author":"Mihaila","year":"2015","journal-title":"Biomed. Pap. Med. Fac. Univ. Palacky. Olomouc Czech Repub."},{"key":"10.1016\/j.ejmech.2017.07.031_bib118","doi-asserted-by":"crossref","first-page":"3433","DOI":"10.1002\/cncr.26621","article-title":"Inhibition of the NADPH oxidase regulates heme oxygenase 1 expression in chronic myeloid leukemia","volume":"118","author":"Singh","year":"2012","journal-title":"Cancer"},{"key":"10.1016\/j.ejmech.2017.07.031_bib119","doi-asserted-by":"crossref","first-page":"543","DOI":"10.3892\/mmr.2014.2167","article-title":"Phenethyl isothiocyanate inhibits growth of human chronic myeloid leukemia K562 cells via reactive oxygen species generation and caspases","volume":"10","author":"Wang","year":"2014","journal-title":"Mol. Med. Rep."},{"key":"10.1016\/j.ejmech.2017.07.031_bib120","doi-asserted-by":"crossref","first-page":"51","DOI":"10.2174\/156800912798888992","article-title":"The Hsp32 inhibitors SMA-ZnPP and PEG-ZnPP exert major growth-inhibitory effects on D34+\/CD38+ and CD34+\/CD38- AML progenitor cells","volume":"12","author":"Herrmann","year":"2012","journal-title":"Curr. Cancer Drug Targets"},{"key":"10.1016\/j.ejmech.2017.07.031_bib121","first-page":"S4","article-title":"Selective inhibition of hemeoxygenase-1 as a novel therapeutic target for anticancer treatment","author":"Yadav","year":"2011","journal-title":"J.\u00a0Nanomedic Nanotechnol."},{"key":"10.1016\/j.ejmech.2017.07.031_bib122","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1179\/1607845414Y.0000000212","article-title":"Heme oxygenase-1 plays a crucial role in chemoresistance in acute myeloid leukemia","volume":"20","author":"Zhe","year":"2015","journal-title":"Hematology"},{"key":"10.1016\/j.ejmech.2017.07.031_bib123","doi-asserted-by":"crossref","first-page":"1823","DOI":"10.7314\/APJCP.2014.15.4.1823","article-title":"HIF-1alpha and GLUT1 gene expression is associated with chemoresistance of acute myeloid leukemia","volume":"15","author":"Song","year":"2014","journal-title":"Asian Pac J. Cancer Prev."},{"key":"10.1016\/j.ejmech.2017.07.031_bib124","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1016\/j.leukres.2015.02.009","article-title":"Heme oxygenase-1 suppresses the apoptosis of acute myeloid leukemia cells via the JNK\/c-JUN signaling pathway","volume":"39","author":"Lin","year":"2015","journal-title":"Leuk. Res."},{"key":"10.1016\/j.ejmech.2017.07.031_bib125","doi-asserted-by":"crossref","first-page":"5994","DOI":"10.4238\/2015.June.1.17","article-title":"Proapoptotic effects of heme oxygenase-1 inhibitor on Kasumi-1 cells via the ATF4\/CHOP\/Ire-1alpha pathway","volume":"14","author":"Wei","year":"2015","journal-title":"Genet. Mol. Res."},{"key":"10.1016\/j.ejmech.2017.07.031_bib126","doi-asserted-by":"crossref","first-page":"2373","DOI":"10.3892\/ijo.2014.2661","article-title":"Potential crosstalk of Ca2+-ROS-dependent mechanism involved in apoptosis of Kasumi-1 cells mediated by heme oxygenase-1 small interfering RNA","volume":"45","author":"Wei","year":"2014","journal-title":"Int. J. Oncol."},{"key":"10.1016\/j.ejmech.2017.07.031_bib127","doi-asserted-by":"crossref","first-page":"3793","DOI":"10.1182\/blood-2007-07-104042","article-title":"HO-1 underlies resistance of AML cells to TNF-induced apoptosis","volume":"111","author":"Rushworth","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.ejmech.2017.07.031_bib128","doi-asserted-by":"crossref","first-page":"2973","DOI":"10.1158\/0008-5472.CAN-09-3407","article-title":"NF-kappaB-inhibited acute myeloid leukemia cells are rescued from apoptosis by heme oxygenase-1 induction","volume":"70","author":"Rushworth","year":"2010","journal-title":"Cancer Res."},{"key":"10.1016\/j.ejmech.2017.07.031_bib129","doi-asserted-by":"crossref","first-page":"658","DOI":"10.18632\/oncotarget.321","article-title":"Protection of acute myeloid leukaemia cells from apoptosis induced by front-line chemotherapeutics is mediated by haem oxygenase-1","volume":"2","author":"Heasman","year":"2011","journal-title":"Oncotarget"},{"key":"10.1016\/j.ejmech.2017.07.031_bib130","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1111\/j.1349-7006.2010.01550.x","article-title":"Expression of heme oxygenase-1 in human leukemic cells and its regulation by transcriptional repressor Bach1","volume":"101","author":"Miyazaki","year":"2010","journal-title":"Cancer Sci."},{"key":"10.1016\/j.ejmech.2017.07.031_bib131","doi-asserted-by":"crossref","first-page":"5216","DOI":"10.1093\/emboj\/cdf516","article-title":"Hemoprotein Bach1 regulates enhancer availability of heme oxygenase-1 gene","volume":"21","author":"Sun","year":"2002","journal-title":"EMBO J."},{"key":"10.1016\/j.ejmech.2017.07.031_bib132","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1089\/ars.2006.8.107","article-title":"The heme-Bach1 pathway in the regulation of oxidative stress response and erythroid differentiation","volume":"8","author":"Igarashi","year":"2006","journal-title":"Antioxid. Redox Signal"},{"key":"10.1016\/j.ejmech.2017.07.031_bib133","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1016\/j.phrs.2008.09.003","article-title":"Dual roles of Nrf2 in cancer","volume":"58","author":"Lau","year":"2008","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.ejmech.2017.07.031_bib134","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.3892\/ijo.2015.2835","article-title":"Silencing HO-1 sensitizes SKM-1 cells to apoptosis induced by low concentration 5-azacytidine through enhancing p16 demethylation","volume":"46","author":"Wang","year":"2015","journal-title":"Int. J. Oncol."},{"key":"10.1016\/j.ejmech.2017.07.031_bib135","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1097\/CAD.0000000000000068","article-title":"Crucial role of heme oxygenase-1 in the sensitivity of acute myeloid leukemia cell line Kasumi-1 to ursolic acid","volume":"25","author":"Ma","year":"2014","journal-title":"Anticancer Drugs"},{"key":"10.1016\/j.ejmech.2017.07.031_bib136","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1080\/15384047.2016.1177679","article-title":"HIF-1alpha inhibition by 2-methoxyestradiol induces cell death via activation of the mitochondrial apoptotic pathway in acute myeloid leukemia","volume":"17","author":"Zhe","year":"2016","journal-title":"Cancer Biol. Ther."},{"key":"10.1016\/j.ejmech.2017.07.031_bib137","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1007\/s11899-015-0255-4","article-title":"Targeting the microenvironment in acute myeloid leukemia","volume":"10","author":"Rashidi","year":"2015","journal-title":"Curr. Hematol. Malig. Rep."},{"key":"10.1016\/j.ejmech.2017.07.031_bib138","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1111\/bjh.14036","article-title":"Anti-leukaemic effects induced by APR-246 are dependent on induction of oxidative stress and the NFE2L2\/HMOX1 axis that can be targeted by PI3K and mTOR inhibitors in acute myeloid leukaemia cells","volume":"174","author":"Ali","year":"2016","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.ejmech.2017.07.031_bib139","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1002\/gcc.20193","article-title":"Acute myeloid leukemia with a complex aberrant karyotype is a distinct biological entity characterized by genomic imbalances and a specific gene expression profile","volume":"43","author":"Schoch","year":"2005","journal-title":"Genes Chromosom. Cancer"},{"key":"10.1016\/j.ejmech.2017.07.031_bib140","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1038\/bjc.2014.380","article-title":"Retinoic acid synergizes ATO-mediated cytotoxicity by precluding Nrf2 activity in AML cells","volume":"111","author":"Valenzuela","year":"2014","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.ejmech.2017.07.031_bib141","doi-asserted-by":"crossref","first-page":"e948","DOI":"10.1038\/cddis.2013.467","article-title":"Low-dose triptolide in combination with idarubicin induces apoptosis in AML leukemic stem-like KG1a cell line by modulation of the intrinsic and extrinsic factors","volume":"4","author":"Liu","year":"2013","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.ejmech.2017.07.031_bib142","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1002\/cyto.b.20403","article-title":"Determination of P-glycoprotein, MDR-related protein 1, breast cancer resistance protein, and lung-resistance protein expression in leukemic stem cells of acute myeloid leukemia","volume":"74","author":"de Figueiredo-Pontes","year":"2008","journal-title":"Cytom. B Clin. Cytom."},{"key":"10.1016\/j.ejmech.2017.07.031_bib143","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1039\/c2np00088a","article-title":"Triptolide: structural modifications, structure-activity relationships, bioactivities, clinical development and mechanisms","volume":"29","author":"Zhou","year":"2012","journal-title":"Nat. Prod. Rep."},{"key":"10.1016\/j.ejmech.2017.07.031_bib144","doi-asserted-by":"crossref","first-page":"10074","DOI":"10.3390\/molecules190710074","article-title":"Molecular and chemical regulation of the Keap1-Nrf2 signaling pathway","volume":"19","author":"Keum","year":"2014","journal-title":"Molecules"},{"key":"10.1016\/j.ejmech.2017.07.031_bib145","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1111\/cas.12988","article-title":"Withaferin A suppresses the growth of myelodysplasia and leukemia cell lines by inhibiting cell cycle progression","volume":"107","author":"Okamoto","year":"2016","journal-title":"Cancer Sci."},{"key":"10.1016\/j.ejmech.2017.07.031_bib146","doi-asserted-by":"crossref","first-page":"290","DOI":"10.3390\/ijms17030290","article-title":"Withaferin-a\u2013a natural anticancer agent with pleitropic mechanisms of action","volume":"17","author":"Lee","year":"2016","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ejmech.2017.07.031_bib147","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1179\/joc.2011.23.3.150","article-title":"Maesopsin 4-O-beta-D-glucoside, a natural compound isolated from the leaves of Artocarpus tonkinensis, inhibits proliferation and up-regulates HMOX1, SRXN1 and BCAS3 in acute myeloid leukemia","volume":"23","author":"Pozzesi","year":"2011","journal-title":"J.\u00a0Chemother."},{"key":"10.1016\/j.ejmech.2017.07.031_bib148","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/j.apjtm.2016.03.012","article-title":"In\u00a0vivo anticancer activity of maesopsin 4-O-beta-glucoside isolated from leaves of Artocarpus tonkinensis A. Chev. Ex Gagnep","volume":"9","author":"Thuy","year":"2016","journal-title":"Asian Pac J. Trop. Med."},{"key":"10.1016\/j.ejmech.2017.07.031_bib149","doi-asserted-by":"crossref","first-page":"4163","DOI":"10.1182\/blood-2004-10-4135","article-title":"The sesquiterpene lactone parthenolide induces apoptosis of human acute myelogenous leukemia stem and progenitor cells","volume":"105","author":"Guzman","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.ejmech.2017.07.031_bib150","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1007\/s10753-011-9346-0","article-title":"Parthenolide, a sesquiterpene lactone, expresses multiple anti-cancer and anti-inflammatory activities","volume":"35","author":"Mathema","year":"2012","journal-title":"Inflammation"},{"key":"10.1016\/j.ejmech.2017.07.031_bib151","doi-asserted-by":"crossref","first-page":"4427","DOI":"10.1182\/blood-2007-05-090621","article-title":"An orally bioavailable parthenolide analog selectively eradicates acute myelogenous leukemia stem and progenitor cells","volume":"110","author":"Guzman","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.ejmech.2017.07.031_bib152","doi-asserted-by":"crossref","first-page":"1982","DOI":"10.1158\/1535-7163.MCT-05-0247","article-title":"Guggulsterones induce apoptosis and differentiation in acute myeloid leukemia: identification of isomer-specific antileukemic activities of the pregnadienedione structure","volume":"4","author":"Samudio","year":"2005","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.ejmech.2017.07.031_bib153","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1146\/annurev.nutr.23.011702.073102","article-title":"GUGULIPID: a natural cholesterol-lowering agent","volume":"23","author":"Urizar","year":"2003","journal-title":"Annu. Rev. Nutr."},{"key":"10.1016\/j.ejmech.2017.07.031_bib154","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.1159\/000447852","article-title":"Identification of heme Oxygenase-1 as a novel predictor of hematopoietic stem cell transplantation outcomes in acute leukemia","volume":"39","author":"Lu","year":"2016","journal-title":"Cell Physiol. Biochem."},{"key":"10.1016\/j.ejmech.2017.07.031_bib155","doi-asserted-by":"crossref","first-page":"3137","DOI":"10.3892\/ol.2015.3644","article-title":"HO-1, RET and PML as possible markers for risk stratification of acute myelocytic leukemia and prognostic evaluation","volume":"10","author":"Yu","year":"2015","journal-title":"Oncol. Lett."}],"container-title":["European Journal of Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523417305536?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523417305536?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,6,24]],"date-time":"2025-06-24T16:41:27Z","timestamp":1750783287000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0223523417305536"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,12]]},"references-count":155,"alternative-id":["S0223523417305536"],"URL":"https:\/\/doi.org\/10.1016\/j.ejmech.2017.07.031","relation":{},"ISSN":["0223-5234"],"issn-type":[{"type":"print","value":"0223-5234"}],"subject":[],"published":{"date-parts":[[2017,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Heme oxygenase-1: A new druggable target in the management of chronic and acute myeloid leukemia","name":"articletitle","label":"Article Title"},{"value":"European Journal of Medicinal Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejmech.2017.07.031","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}